Roche’s astegolimab met the main goal of one pivotal COPD study but failed another, mirroring the mixed results recently posted by a Regeneron Pharmaceuticals COPD drug candidate that goes after the same target. Biologics are a new treatment option for COPD following approvals of antibodies from Sanofi and GSK.
The post Roche Reports Mixed Data for Drug Trying to Jump on the Biologic Bandwagon in COPD appeared first on MedCity News.
